Price / Earningsn/mnet loss, so no earnings multiple, FY2025
Price / Book1.1xon $112.4M equity, Q3 FY2026
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Source SEC Filings (10-K/10-Q)Latest period Q3 FY2026, ended Jun 30, 2026ReportedCurrency USDFYE September
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 28, 2026.
Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVXL SEC filings page.
This page shows Anavex Life Sciences (AVXL) financial statements, including the
income statement, balance sheet, cash flow statement, and key financial ratios.
View 15 years of annual fundamentals and quarterly data, with year-over-year
growth rates and compound annual growth rates (CAGR).
All figures are derived from SEC filings (10-K and 10-Q reports).
Rhea AIAVXLFY2025
Anavex operates as a research-led development business: operating losses persist while its asset base and financing have contracted.
In FY2025, the net loss of $46.4M exceeded the cash outflow of $39.0M, showing that reported loss and cash use do not move one-for-one. Meanwhile, assets fell 23.4% from FY2024 while financing cash flow was $9.4M, indicating a shrinking resource base alongside less external funding.
Expense mix shifted in FY2025: research and development fell 10.1% while selling, general and administrative costs rose 25.2%, moving spending toward administration rather than producing a broad cost retreat. The operating loss remained substantial at $51.4M, despite being narrower than $52.9M in FY2024.
Reported liabilities were just 8.6% of assets, and total liabilities fell 41.5% from FY2024, so the balance sheet is not principally burdened by reported obligations. The liquidity comparison represented 31.5 months of reported outflow, but FY2025 return on assets was negative 44.7%, reflecting losses relative to the reduced asset base.
Financial Health Signals
Financial health score not available
Anavex Life Sciences does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Piotroski F-ScorePartial
1/5
Anavex Life Sciences passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Earnings QualityNo Cash Backing
N/A
Anavex Life Sciences reported a net loss of $46.4M while operations used $39.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Anavex Life Sciences reported $7.8M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
EPS (Diluted)
$0.08
YoYn/m
Anavex Life Sciences earned $0.08 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Revenue
Not reported for Q3 2026.
EBITDA
Not reported for Q3 2026.
Cash & Balance Sheet
Cash & Debt
$118.3M
YoY+17.0%
QoQ-7.1%
5Y CAGR-5.6%
10Y CAGR+28.4%
Anavex Life Sciences held $118.3M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Shares Outstanding
93M
YoY+7.9%
Anavex Life Sciences had 93M shares outstanding in Q3 2026. This represents an increase of 7.9% from the same quarter a year earlier.
Free Cash Flow
Not reported for Q3 2026.
Dividends Per Share
Not reported for Q3 2026.
Margins & Returns
Return on Equity
7.0%
YoY+21.5pp
QoQ+11.3pp
Anavex Life Sciences's quarterly ROE was 7.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 21.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.3 percentage points.
Gross Margin
Not reported for Q3 2026.
Operating Margin
Not reported for Q3 2026.
Net Margin
Not reported for Q3 2026.
Capital Allocation
None of these metrics is reported for Q3 2026.
AVXL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AVXL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
AVXL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AVXL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
No, Anavex Life Sciences (AVXL) reported a net loss of $46.4M in fiscal year 2025.
What is Anavex Life Sciences's earnings per share (EPS)?
Anavex Life Sciences (AVXL) reported diluted earnings per share of -$0.54 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Anavex Life Sciences's return on equity (ROE)?
Anavex Life Sciences (AVXL) has a return on equity of -48.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Anavex Life Sciences's operating cash flow?
Anavex Life Sciences (AVXL) recorded an outflow of $39.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Anavex Life Sciences's total assets?
Anavex Life Sciences (AVXL) had $103.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Anavex Life Sciences spend on research and development?
Anavex Life Sciences (AVXL) invested $37.6M in research and development during fiscal year 2025.
How many shares does Anavex Life Sciences have outstanding?
Anavex Life Sciences (AVXL) had 89M shares outstanding as of fiscal year 2025.
What is Anavex Life Sciences's liabilities-to-equity ratio?
Anavex Life Sciences (AVXL) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Anavex Life Sciences's return on assets (ROA)?
Anavex Life Sciences (AVXL) had a return on assets of -44.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Anavex Life Sciences's P/E ratio?
Anavex Life Sciences (AVXL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $121.4M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Anavex Life Sciences's price-to-sales ratio?
Anavex Life Sciences (AVXL) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $121.4M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Anavex Life Sciences's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Anavex Life Sciences (AVXL) held $102.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.0M over that year. Dividing the one by the other, the reported balance equals about 32 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Anavex Life Sciences's Piotroski F-Score?
Anavex Life Sciences (AVXL) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Anavex Life Sciences's earnings high quality?
Anavex Life Sciences (AVXL) reported a net loss of $46.4M while operations used $39.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
